Predictive Value of PARIS® Test in Ovarian Cancer Patients at 2021 AACR Annual Conference
Read More
Precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids
Read More
SEngine to present Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
Read More
Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine
Read More
Clinical Utility demonstrated in Metastatic Colorectal Cancer Study Published in AACR’s Clinical Cancer Research
Read More
Predictive value of the PARIS® Test for personalized treatment in cholangiocarcinoma
Read More
Results of the PARIS Test showed a 92% correlation between organoid drug sensitivity and patient response to previous treatments
Read More
PARIS® Test for Oncology Drugs Based on Retrospective Analysis presented at 2020 ASCO Annual Meeting
Read More
Predictive Value of PARIS® Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients presented at 2020 AACR Virtual Meeting Session II
Read More
February 2019 Pulitzer Prize Winner to Lead Scientific Advisory Board
Read More
SEngine Precision Medicine Raises $5.1 Million Series A
Read More